Aiming For More Deals, Shire Christens Regenerative Medicine Unit
This article was originally published in The Pink Sheet Daily
The company hopes its newest division will mirror the growth of its rare disease unit, which was built largely through aggressive business development.
You may also be interested in...
The early successes enjoyed by new autologous, cell-based cancer therapies, as well as new advances in gene therapy and regenerative medicine, have reignited interest at Big Pharma in these advanced treatments, said partnering executives at the recent Therapeutic Area Partnerships meeting in Boston.
With its third acquisition this year, Shire gains Phase III Lifitegrast in development for dry eye disease. It expects to launch the product in the U.S. in 2016.
California’s stem cell agency still has nearly two billion dollars to grant. But with recent stem cell breakthroughs slow to translate, will venture backers and drug firms help build the ecosystem California citizens imagined in 2004 when they voted to make the state a beacon for the science?